This study compared the incidence of clinical extensive chronic graft-versus-host disease (GVHD), transplantation-related mortality, survival, and relapsefree survival among recipients randomly assigned to receive a 24-month or a 6-month course of cyclosporine prophylaxis after transplantation of allogeneic marrow from an HLA-identical sibling or alternative donor. Patients who did not have clinical manifestations of chronic GVHD on day 80 after transplantation were eligible for the study if they previously had acute GVHD or if a skin biopsy showed histologic evidence of chronic GVHD. Clinical extensive chronic GVHD developed in 35 of the 89 patients (39%) in the 24-month group and 37 of the 73 patients (51%) in the 6-month group. The hazard of developing chronic GVHD was not significantly different in the 2 groups (hazard ratio = 0.76; 95% confidence interval, 0.48-1.21; P = .25). In addition, there were no significant differences between the 2 groups in transplantation-related mortality, survival, or disease-free survival. © 2001 by The American Society of Hematology.
Kansu, E., Gooley, T., Flowers, M. E. D., Anasetti, C., Joachim Deeg, H., Nash, R. A., … Martin, P. J. (2001). Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: A prospective randomized clinical trial. Blood, 98(13), 3868–3870. https://doi.org/10.1182/blood.V98.13.3868